This 2013 review evaluates lorcaserin, a selective 5-HT₂C receptor agonist, for chronic weight management in obese and overweight adults. Clinical trials demonstrated that lorcaserin, as an adjunct to diet and exercise, led to significant weight loss compared to placebo. After 12 months, a higher proportion of lorcaserin-treated patients achieved ≥5%
This 2013 review discusses pharmacologic options for obesity management, emphasizing the role of medications as adjuncts to lifestyle modifications. At the time, four FDA-approved drugs were available: orlistat, lorcaserin (Belviq), phentermine/topiramate (Qsymia), and naltrexone/bupropion (Contrave). Orlistat functions by inhibiting fat absorption, while the others act centrally to suppress appetite. Clinical
This 2018 systematic review and network meta-analysis evaluated the impact of FDA-approved weight-loss medications—phentermine-topiramate, liraglutide, naltrexone-bupropion, lorcaserin, and orlistat—on cardiometabolic risk factors in obese adults. Analyzing 28 randomized controlled trials encompassing 29,018 participants, the study found that these medications led to modest reductions in fasting blood glucose (mean decrease of
This 2013 review discusses the pharmacology of serotonin (5-HT) receptors and highlights two selective 5-HT receptor subtype-targeted drugs: lorcaserin and pimavanserin. Lorcaserin is a 5-HT₂C receptor agonist approved for obesity treatment, promoting satiety through hypothalamic activation. Pimavanserin is a 5-HT₂A receptor inverse agonist approved for Parkinson’s disease psychosis, offering antipsychotic
This 2010 double-blind, randomized controlled trial (BLOOM) evaluated the efficacy and safety of lorcaserin, a selective 5-HT₂C receptor agonist, in 3,182 overweight or obese adults over 52 weeks. Participants received lorcaserin 10 mg twice daily or placebo, alongside lifestyle counseling. At 1 year, 47.5% of the lorcaserin group lost ≥5%
